1-4 of 4
Deborah McCue
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Long-term outcome of acute promyelocytic leukemia treated with all- trans -retinoic acid, arsenic trioxide, and gemtuzumab

Clinical Trials & Observations
Yasmin Abaza, Hagop Kantarjian, Guillermo Garcia-Manero, Elihu Estey, Gautam Borthakur, Elias Jabbour, Stefan Faderl, Susan O’Brien, William Wierda, Sherry Pierce, Mark Brandt, Deborah McCue, Rajyalakshmi Luthra, Keyur Patel, Steven Kornblau, Tapan Kadia, Naval Daver, Courtney DiNardo, Nitin Jain, Srdan Verstovsek, Alessandra Ferrajoli, Michael Andreeff, Marina Konopleva, Zeev Estrov, Maria Foudray, David McCue, Jorge Cortes, Farhad Ravandi
Journal: Blood
Blood (2017) 129 (10): 1275–1283.
https://doi.org/10.1182/blood-2016-09-736686
Published: 2017
Journal Articles

Outcomes Of Repeated Administration Of Rasburicase In Recurrent Cycles For Patients With Leukemia

Alice C. Wang, PharmD, Deborah McCue, PharmD, Farhad Ravandi, MD, Gautam Borthakur, MD, Deborah A. Thomas, MD, Stefan Faderl, MD, William G. Wierda, MD, PhD, Jorge E. Cortes, MD
Journal: Blood
Blood (2013) 122 (21): 3888.
https://doi.org/10.1182/blood.V122.21.3888.3888
Published: 2013
Journal Articles

Final Report of a Phase II Trial of Vorinostat with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Guillermo Garcia-Manero, Francesco Paolo Tambaro, MD, PhD, Nebiyou Bekele, Hui Yang, Farhad Ravandi, MD, Elias Jabbour, Gautam Borthakur, Tapan Kadia, Marina Konopleva, M.D., Ph.D., Stefan Faderl, MD, Jorge E. Cortes, Mark Brandt, BS, Yumin Hu, PhD, Deborah McCue, Willie Mae Newsome, RN, Sherry Pierce, RN, BS, Marcos DeLima, MD, Hagop M. Kantarjian
Journal: Blood
Blood (2011) 118 (21): 763.
https://doi.org/10.1182/blood.V118.21.763.763
Published: 2011
Journal Articles

Palonosetron (PALO) Given Daily for up to 5 Days Is Significantly Better Than Ondansetron (ONDA) in the Prevention of Delayed CINV in Patients (pts) with Acute Myelogenous Leukemia (AML).

Gloria Mattiuzzi, MD, Jorge Cortes, MD, Deborah McCue, PhDP, B. Nebiyou Bekele, PhD, Lianchun Xiao, Gautam Borthakur, MD, Hagop Kantarjian, MD
Journal: Blood
Blood (2009) 114 (22): 993.
https://doi.org/10.1182/blood.V114.22.993.993
Published: 2009